Latin American Market | Growth Is Real, But Requires Careful Strategic Planning

Similar to the Southeast Asian market discussed in previous installments, “Latin America” is merely a geographical umbrella term; when broken down, each sub‑market has its own set of rules and its own window of opportunity.

These six countries each speak two languages—Brazil speaks Portuguese, while the other five speak Spanish. There are six independent registration systems, six sets of import regulations, and six distinct procurement logics.

Together, Brazil, Colombia, Argentina, and Peru have a combined population of nearly 350 million. Aging populations, the rising burden of chronic diseases, and the need to upgrade medical equipment—all reflect genuine demand. However, the presence of a market does not necessarily mean your product can successfully penetrate it.

The same product may win public tenders in Brazil by offering the lowest price, while in Mexico it might succeed through informal channels backed by FDA approval. That’s why choosing the right entry point is far more critical than hoping to cover all of South America from the outset.

First, ask yourself three questions:

Which country is the best entry point for my product?

Should we pursue public procurement, private hospitals, or distribution channels?

Which country’s market access requirements best align with my existing registration information?

This is the most costly mistake.

Any issues that arise will significantly slow down the overall market progress.

All six Latin American countries require local representatives to hold certification. In Brazil, this is called BRH; in Mexico, Titular; and in Argentina, AAR—these entities hold the legal ownership of the registration certificate. Once a registration is assigned to a particular distributor and the contract lacks provisions for transfer or withdrawal, switching distribution channels effectively necessitates re‑registration. As for the registration fee, that’s manageable; but spending six to twelve months on it is simply too time‑consuming to afford.

So before signing with an agent, make sure to confirm at least four things.

What risk level does the product fall under locally?

Are the current registration details sufficient?

Who bears the registration fees and subsequent maintenance costs?

Who is the registrant?

Can the registration be transferred after the cooperation ends?

Agency cooperation and registration arrangements must be discussed together. Who is responsible for registration, whether it is exclusive, whether additional importers can be brought in, and how matters will be handled upon termination—these should all be stipulated in the contract in advance, rather than being addressed only after problems arise.

Many manufacturers, upon arriving in Latin America, say their first words: “I want to find the largest distributor in this country.”

In reality, major distributors often already have a full lineup of established brands. Your product may end up being just one among many options in their catalog. Brazil’s largest platform‑based importer, VR Medical, held 234 Chinese product registrations as of 2025—so where would your product rank among those 234 SKUs?

On the contrary, a mid-sized specialized distributor that happens to be missing your product line is actually willing to assign dedicated personnel to handle registration, provide training, and develop hospital accounts for you.

To assess a dealer, consider four key questions.

How important is your product to him?

Is there a dedicated person in charge?

Which customers are planned for development in the first phase?

What resources is he willing to invest in your product?

The right partner isn’t necessarily the biggest; it’s the one that’s willing to make your product their top priority.

In South America, in addition to evaluating product pricing, buyers also assess whether you’re committed to this market over the long term, whether you can respond promptly when issues arise, and whether you’ll stay on board to resolve challenges.

A lively conversation at the trade show doesn’t necessarily mean an immediate order. A slow follow-up after the event doesn’t equate to a rejection either. True collaboration typically unfolds through sustained follow-up, product testing, repeated meetings, and even joint visits to hospitals with distributors—only then does progress gradually take shape.

Trust is built on actions, not just attitudes. When a client is willing to confirm registration requirements, arrange product testing, designate a point of contact, and outline target customers and next steps, that’s when you can truly say the collaboration has moved forward.

In South America, contracts clearly define rights and obligations, while trust and sustained commitment determine whether a partnership can succeed.

Latin American countries are simultaneously advancing regulatory reforms, with the overall direction being favorable to imports.

Major medical device markets in Latin America are accelerating the adoption of streamlined market‑entry mechanisms for regulatory‑compliant, low‑risk products, though a unified mutual recognition framework with the FDA and CE has yet to emerge. Mexico has implemented a simplified pathway for devices based on approvals from reference regulatory authorities, with a statutory review period of no more than 30 working days for eligible products. Meanwhile, Argentina has eliminated pre‑clearance requirements for the batch‑by‑batch import of registered Class I and II devices, replacing them with a post‑clearance reporting obligation within 48 hours. Brazil, Colombia, Peru, and Chile also permit, to varying degrees, the use of regulatory frameworks from the United States or the European Union; however, local registration or notification remains typically required. According to an analysis of ANVISA’s publicly available database through March 2026, China has surpassed the United States to become the largest source country of medical devices registered in Brazil.

But in the opposite direction, the “race to register” has also swept across Latin America: in 2025, ANVISA processed a record 10,639 new registrations—though this window of opportunity will not remain open indefinitely.

Having discussed Latin America, it’s essential to mention the United States, as the two regions enjoy a complementary relationship.

The United States boasts an import value of US$74.08 billion, ranking first globally. Under the FDA’s 510(k) pathway, the median review time is 142 days, with an approval rate of 85%, making it one of the most cost-effective medical device registration routes worldwide. However, high tariffs, stringent compliance requirements, and the gradual exclusion of low‑value product categories are increasingly posing challenges.

Beyond generating profits in the marketplace, the value of the U.S. lies in “leveraging the FDA to drive global influence.” FDA approval serves as a mark of quality across the entire Latin American market. Securing FDA clearance effectively opens half the door to the five major Latin American markets.

One feasible approach is to first secure FDA approval, then leverage that approval to expand into Latin America. The U.S. is a stronghold for established brands, while Latin America represents a growth market.

So, is there a place…

Can you reach both the U.S. market and Latin American buyers simultaneously?

The answer is: Miami.

A crossroads for market resources across two continents | Directly engaging procurement decision-makers from multiple countries—registration for WHX Miami 2027 is now open!

Miami is also known as the “Capital of Latin America.” The volume of air cargo between Miami International Airport and Latin America exceeds that of all other U.S. airports combined. The city boasts the highest concentration of foreign‑trade zones in the United States, where goods can be stored indefinitely, repackaged, and re‑exported to Latin America entirely duty‑free.

The densest concentration of Latin American corporate headquarters and the most vibrant Spanish–Portuguese business network in the entire United States are both located here.

WHX Miami capitalizes on this strategic location. At the 2026 edition, 1,214 companies from 55 countries will participate, with over 400 exhibitors from China, making it the largest medical trade show in the Americas.

The exhibition’s core audience comprises major distributors across Latin America—channel partners from Brazil, Mexico, Colombia, Argentina, Chile, and Peru have all gathered in Miami.

Meanwhile, U.S. domestic buyers were also present at the exhibition.

A trip to Miami—on the left, Latin American distributors; on the right, U.S. buyers. One exhibition, two markets covered.